Clinical, Anatomic Improvements With Dupilumab in Eosinophilic Esophagitis Study
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
Eosinophilic Esophagitis
Long-Term Eosinophilic Esophagitis Successfully Treated With JAK Inhibitor
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
Updated Eosinophilic Esophagitis Guidelines Encourage Interdisciplinary Collaboration
New guidelines on eosinophilic esophagitis management were recently developed with the aim of informing treatment decisions among pediatric and adult allergists and gastroenterologists.
Budesonide Oral Suspension Improves Dysphagia in Eosinophilic Esophagitis
Budesonide oral suspension was associated with improvements in dysphagia in patients with eosinophilic esophagitis.
Benralizumab Receives Orphan Drug Status for Eosinophilic Esophagitis
The FDA has granted Orphan Drug designation to benralizumab for the treatment of eosinophilic esophagitis.
Role of Environmental Risk Factors in Eosinophilic Esophagitis
Potential risk factors for eosinophilic esophagitis include antibiotic use in infancy and behaviors such as smoking and alcohol intake.
-
Loading...
-
Loading...
Next post in Allergies
